Your browser is no longer supported. Please, upgrade your browser.
Settings
ADXS Advaxis, Inc. daily Stock Chart
ADXS [NASD]
Advaxis, Inc.
Index- P/E- EPS (ttm)-1.60 Insider Own1.40% Shs Outstand73.02M Perf Week-20.13%
Market Cap44.33M Forward P/E- EPS next Y-0.63 Insider Trans3.37% Shs Float64.30M Perf Month-29.34%
Income-71.20M PEG- EPS next Q-0.15 Inst Own23.90% Short Float5.12% Perf Quarter-59.79%
Sales6.70M P/S6.62 EPS this Y-11.00% Inst Trans30.81% Short Ratio4.14 Perf Half Y-62.98%
Book/sh0.63 P/B0.96 EPS next Y42.20% ROA-91.50% Target Price3.33 Perf Year-83.98%
Cash/sh0.54 P/C1.13 EPS next 5Y- ROE-165.20% 52W Range0.61 - 3.85 Perf YTD-78.62%
Dividend- P/FCF- EPS past 5Y14.30% ROI-173.30% 52W High-84.16% Beta2.32
Dividend %- Quick Ratio3.90 Sales past 5Y- Gross Margin- 52W Low0.44% ATR0.06
Employees108 Current Ratio3.90 Sales Q/Q-64.50% Oper. Margin- RSI (14)24.57 Volatility8.24% 7.57%
OptionableYes Debt/Eq0.00 EPS Q/Q66.90% Profit Margin- Rel Volume1.52 Prev Close0.61
ShortableYes LT Debt/Eq0.00 EarningsSep 10 Payout- Avg Volume793.60K Price0.61
Recom2.30 SMA20-23.82% SMA50-41.63% SMA200-64.53% Volume366,481 Change0.44%
Aug-03-16Reiterated Barclays Overweight $15 → $20
Sep-22-15Initiated Barclays Overweight $40
Sep-11-15Initiated Guggenheim Buy $30
Jun-16-15Reiterated H.C. Wainwright Buy $25 → $30
May-15-15Initiated Jefferies Buy $27
May-14-15Initiated MLV & Co Buy $34
Oct-23-14Initiated H.C. Wainwright Buy $8
Feb-18-14Initiated Aegis Capital Buy $18
Feb-10-14Initiated Noble Financial Buy $12
Oct-18-18 09:25AM  Investor Expectations to Drive Momentum within Aethlon Medical, Jaguar Animal Health, Advaxis, Forestar Group, Platform Specialty Products, and AVEO Pharmaceuticals Discovering Underlying Factors of Influence GlobeNewswire
Sep-25-18 08:00AM  Advaxis to Present at the Cantor Fitzgerald Global Healthcare Conference Business Wire
Sep-12-18 08:26AM  The Daily Biotech Pulse: Foamix Jumps on Data, Positive Results for Galapagos-Gilead's Rheumatoid Arthritis Drug, Bausch Health Trims Debt Benzinga
Sep-11-18 12:00PM  Advaxis Inc (NASDAQ:ADXS): How Much Growth Is Left In Healthcare? Simply Wall St. -11.09%
09:20AM  Advaxis Announces Closing of Its Public Offering of Common Stock and Warrants Business Wire
08:25AM  The Daily Biotech Pulse: Advaxis Posts Narrower Loss, Endocyte Announces $175M Offering, Leadership Transition At Insulet Benzinga
Sep-10-18 04:35PM  Advaxis: Fiscal 3Q Earnings Snapshot Associated Press -6.25%
04:30PM  Advaxis Reports Fiscal 2018 Third Quarter Business Highlights and Financial Results Business Wire
Sep-07-18 09:25AM  Advaxis Announces Pricing of Its Public Offering of Common Stock and Warrants Business Wire -28.67%
07:55AM  The Daily Biotech Pulse: Amgen-AstraZeneca, Boston Scientific Opens Wallet, Advaxis Offering Benzinga
Sep-06-18 05:08PM  Advaxis, Inc. Announces Proposed Underwritten Public Offering of Common Stock and Warrants Business Wire -5.92%
Sep-04-18 08:00AM  Advaxis Licenses ADXS-HER2 to OS Therapies for Evaluation in the Treatment of Osteosarcoma Business Wire
Aug-28-18 07:45AM  Recent Analysis Shows Liberty TripAdvisor, Control4, Ferro, Advaxis, Frontier Communications, and Newpark Resources Market Influences Renewed Outlook, Key Drivers of Growth GlobeNewswire
Jul-30-18 08:00AM  Advaxis Announces FDA Allowance of IND Application for ADXS-HOT Drug Candidate for Non-Small Cell Lung Cancer Business Wire
Jul-26-18 07:20AM  Free Technical Research on Advaxis and Three More Biotech Equities ACCESSWIRE -6.67%
Jul-18-18 08:08AM  Biotech Stock Roundup: AMGN Resubmits Evenity BLA, Advaxis Soars, Regulatory Updates Zacks
Jul-17-18 07:10AM  Blog Exposure - FDA Lifts Clinical Hold on Advaxis' Cancer Drug ACCESSWIRE
Jul-16-18 10:45AM  Biotech Companies with Great Futures ACCESSWIRE +7.46%
Jul-13-18 11:37AM  Advaxis Shares Soar After FDA Lifts Clinical Hold On Cancer Drug Benzinga +9.84%
08:18AM  Advaxis shares rise 68% after FDA lifts clinical hold on its drug trial MarketWatch
08:00AM  Advaxis Announces FDA Lifts Clinical Hold on Phase 1/2 Combination Study of Axalimogene Filolisbac with Durvalumab Business Wire
Jul-10-18 08:00AM  Advaxis Provides Update on MAA Filing and ADXS-HOT Program Business Wire -8.28%
Jun-28-18 08:15AM  New Research Coverage Highlights Knowles, Advaxis, G-III Apparel Group, LTD, National CineMedia, Haemonetics, and MACOM Technology Solutions Consolidated Revenues, Company Growth, and Expectations for 2018 GlobeNewswire
Jun-18-18 12:18PM  Edited Transcript of ADXS earnings conference call or presentation 7-Jun-18 3:00pm GMT Thomson Reuters StreetEvents
Jun-11-18 08:00AM  Advaxis Announces Dosing of First Patient with ADXS-NEO, an Investigational Customized Immunotherapy Approach Targeting Personal Neoantigens Business Wire
Jun-07-18 09:25AM  Advaxis: Fiscal 2Q Earnings Snapshot Associated Press +11.11%
09:05AM  Advaxis Announces Prioritization of Product Portfolio and Reports Fiscal 2018 Second Quarter Financial Results Business Wire
07:45AM  Complimentary Technical Snapshots on Adverum Biotechnologies and Three More Biotech Stocks ACCESSWIRE
Jun-06-18 08:00AM  Advaxis Appoints Molly Henderson as Chief Financial Officer Business Wire
Jun-01-18 08:00AM  Data Highlighting Advaxis ADXS-PSA Presented at ASCO Annual Meeting Business Wire
May-31-18 08:00AM  Advaxis to Host Business Update and Second Quarter 2018 Financial Results Conference Call on June 7, 2018 Business Wire
May-14-18 08:10AM  Analysis: Positioning to Benefit within Advaxis, e.l.f. Beauty, Heron Therapeutics, PVH, Energy Recovery, and A. O. Smith Research Highlights Growth, Revenue, and Consolidated Results GlobeNewswire +5.62%
May-11-18 08:00AM  Recently Presented Preclinical Data Show Potential for ADXS-NEO as Anti-Cancer Immunotherapy Agent Business Wire +8.54%
Apr-23-18 08:00AM  Advaxis Announces Executive Leadership Changes Business Wire
Apr-17-18 08:00AM  Preclinical Data Highlighting ADXS-Hot as Immunotherapy with Potential to Target Hotspot Cancer Mutations across Multiple Cancer Types Presented in Poster Discussion at The AACR Annual Meeting Business Wire
Apr-03-18 04:39PM  What Is The Future Prospect For Healthcare And Advaxis Inc (NASDAQ:ADXS)? Simply Wall St.
Apr-02-18 08:00AM  Data Highlighting Advaxis ADXS-PSA Accepted as Poster Presentation at the American Society of Clinical Oncology Annual Meeting Business Wire -5.92%
Mar-29-18 07:00AM  Wired News Recro Pharma Publishes Data from Phase-III Trial for IV Meloxicam ACCESSWIRE
Mar-26-18 06:28PM  Advaxis Inc (NASDAQ:ADXS): Does The -36.80% Earnings Drop Reflect A Longer Term Trend? Simply Wall St.
08:00AM  Advaxis Announces Four Poster Presentations Highlighting Lm-based Antigen Delivery Technology at AACR 2018 Business Wire
Mar-13-18 09:05AM  Edited Transcript of ADXS earnings conference call or presentation 12-Mar-18 8:30pm GMT Thomson Reuters StreetEvents -11.76%
08:00AM  Advaxis to Present at Upcoming March Conferences Business Wire
Mar-12-18 05:19PM  Advaxis shares drop as cancer-drug study on hold after death MarketWatch
04:31PM  Advaxis reports 1Q loss Associated Press
04:05PM  Advaxis Reports Fiscal 2018 First Quarter Financial Results and Announces Clinical Hold in Axalimogene Filolisbac Phase 1/2 Combination Study with AstraZenecas IMFINZI® (Durvalumab) Business Wire
08:54AM  Should You Have Advaxis Incs (NASDAQ:ADXS) In Your Portfolio? Simply Wall St.
Mar-09-18 11:06AM  How Do Analysts See Advaxis Inc (NASDAQ:ADXS) Performing Over The Next Few Years? Simply Wall St. +8.37%
08:00AM  Advaxis to Host Business Update and First Quarter 2018 Financial Results Conference Call on March 12, 2018 Business Wire
Mar-08-18 10:27AM  Advaxis Inc (NASDAQ:ADXS): Is Breakeven Near? Simply Wall St.
Feb-22-18 01:05PM  Advaxis looks to raise $20 million via share offering American City Business Journals -28.29%
09:15AM  Advaxis Prices $20.0 Million Public Offering of Common Stock Business Wire
Feb-21-18 04:05PM  Advaxis Announces Proposed Public Offering of Common Stock Business Wire
Feb-13-18 08:30AM  Advaxis Submits Conditional Marketing Authorization Application for Axalimogene Filolisbac for the Second-Line Treatment of Metastatic Cervical Cancer in European Union Business Wire
Feb-12-18 09:15AM  Advaxis Announces Publication of Phase 2 Results Evaluating Axalimogene Filolisbac for the Treatment of Recurrent Metastatic Cervical Cancer in the International Journal of Gynecological Cancer Business Wire +5.32%
08:25AM  Research Report Identifies Diebold, Liberty TripAdvisor, Paycom Software, BJ's Restaurants, Advaxis, and Sanmina with Renewed Outlook Fundamental Analysis, Calculating Forward Movement GlobeNewswire
Jan-29-18 08:00AM  Data Highlighting Advaxis Antigen Delivery Platform Accepted for Multiple Presentations at 2018 Keystone Symposia Conference on Cancer Immunotherapies Business Wire
Jan-25-18 08:00AM  Advaxis Immunotherapy in Combination with Chemoradiation Highlighted as Potential Treatment for Anal Cancer in International Journal of Radiation Oncology Business Wire
Dec-27-17 10:57AM  ETFs with exposure to Advaxis, Inc. : December 27, 2017 Capital Cube
Dec-26-17 09:16AM  Advaxis, Inc. :ADXS-US: Earnings Analysis: Q4, 2017 By the Numbers : December 26, 2017 Capital Cube
Dec-25-17 03:03PM  Edited Transcript of ADXS earnings conference call or presentation 21-Dec-17 3:00pm GMT Thomson Reuters StreetEvents
Dec-21-17 02:02PM  3 Stocks Move on Thursday GuruFocus.com -12.94%
Dec-20-17 04:15PM  Advaxis Reports Fiscal Year 2017 Financial Results and Provides a Business Update Business Wire +12.21%
08:05AM  Aratana Therapeutics Granted Conditional License for a Canine Osteosarcoma Therapeutic PR Newswire
06:05AM  Does Advaxis Incs (NASDAQ:ADXS) -20.1% EPS Decline Reflect A Long-Term Trend? Simply Wall St.
Dec-14-17 08:00AM  Advaxis to Host Business Update and Fiscal Year End 2017 Financial Results Conference Call on December 21, 2017 Business Wire
Dec-13-17 06:34PM  Is Advaxis Inc (NASDAQ:ADXS) As Financially Strong As Its Balance Sheet Indicates? Simply Wall St. +6.67%
Nov-22-17 07:50AM  Analysis: Positioning to Benefit within Diebold, Liberty TripAdvisor, Paycom Software, First American, Advaxis, and Sanmina Research Highlights Growth, Revenue, and Consolidated Results GlobeNewswire
Nov-09-17 08:00AM  Advaxis to Present at the Jefferies 2017 London Healthcare Conference Business Wire
Nov-01-17 08:00AM  Advaxis to Receive $4.5 Million through the New Jersey Economic Development Authority NOL Program Business Wire -6.47%
Oct-03-17 07:20AM  Earnings Review and Free Research Report: Advaxis Reported its Q3 FY17 Results ACCESSWIRE
Sep-21-17 09:05AM  Advaxis to Webcast Company Overview at the Cantor Fitzgerald Global Healthcare Conference Business Wire
Sep-19-17 09:03AM  Two Abstracts Featuring Advaxis Lm-based Candidates Selected for Presentation at the 32nd Annual Society for Immunotherapy Cancer (SITC) Meeting Business Wire
Sep-18-17 09:02AM  Advaxis to Present at Cantor Fitzgerald Global Healthcare Conference Business Wire
07:30AM  Corporate News Blog - EMA Grants Positive CHMP Opinion to Tesaros Ovarian Cancer Drug ACCESSWIRE
Sep-13-17 08:20AM  Today's Research Reports on Stocks to Watch: Advaxis and Heat Biologics ACCESSWIRE -11.31%
Sep-12-17 12:34PM  Here's Why Advaxis, Inc. Stock Is Getting Pummeled Today Motley Fool -19.88%
Sep-11-17 09:39PM  Advaxis reports 3Q loss Associated Press -7.69%
04:01PM  Advaxis Reports Business Update and Third Quarter 2017 Results Business Wire
Sep-08-17 07:20PM  What Does Advaxis Incs (ADXS) Share Price Indicate? Simply Wall St.
Aug-02-17 08:59AM  Advaxis to Present at Third CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference: Translating Science into Survival Business Wire
Jul-13-17 09:06AM  Advaxis Lead Immunotherapy Candidate Continues to Build Recognition Among Industry Leaders Business Wire +5.52%
Jul-06-17 04:48PM  Advaxis CEO Daniel O'Connor resigns Reuters
04:30PM  Advaxis Announces Change in Leadership Business Wire
Jun-26-17 08:55AM  Advaxis Axalimogene Filolisbac Data Selected for Poster Presentation at ESGO 2017 Business Wire
Jun-16-17 09:58AM  Advaxis Breaks Down From Key Support Levels Investopedia
08:00AM  Advaxis to Present at 2017 BIO International Convention Business Wire
Jun-15-17 12:54PM  ETFs with exposure to Advaxis, Inc. : June 15, 2017 Capital Cube -11.23%
Jun-14-17 08:00AM  Advaxis to Be Featured on Worldwide Business with kathy ireland® Business Wire -5.84%
Jun-13-17 12:30PM  Advaxis Details Registrational Trials, EU Regulatory and Commercial Plans at Annual Investor & Analyst Day Business Wire -7.82%
Jun-09-17 08:00AM  Advaxis to Webcast Investor & Analyst Day 2017 Business Wire -5.36%
Jun-08-17 09:17AM  Update: Webcast of Advaxis Presentation at Jefferies 2017 Global Healthcare Conference Now Available Business Wire
Jun-07-17 08:30AM  Advaxis to Present at Jefferies 2017 Global Healthcare Conference Business Wire
08:07AM  Advaxis, Inc. breached its 50 day moving average in a Bullish Manner : ADXS-US : June 7, 2017 Capital Cube
05:01AM  Advaxis reports 2Q loss Associated Press
Jun-05-17 11:50AM  SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating Advaxis, Inc. for Potential Breaches Of Fiduciary Duty By Its Board of Directors PR Newswire
Jun-01-17 08:00AM  Synthetic Genomics Launches cGMP Suite for Pharmaceutical Quality Manufacturing of Synthetic DNA for Advaxis' Clinical Trials PR Newswire
May-30-17 09:29AM  Biotech Movers: Array Shares Rise on Bristol-Myers Collaboration TheStreet.com
06:59AM  Advaxis and Bristol-Myers Squibb Announce Clinical Collaboration to Evaluate ADXS-DUAL and Opdivo (nivolumab) in Metastatic Cervical Cancer Business Wire
05:17AM  How Two Biotechs Fell On Cancer Partnerships With Bristol-Myers Investor's Business Daily
May-18-17 08:00AM  Advaxis to Host Investor & Analyst Day on June 12 Business Wire +5.09%
Advaxis, Inc., a clinical stage biotechnology company, focuses on the discovery, development, and commercialization of Listeria monocytogenes (Lm) technology based immunotherapies in the United States. It is developing Axalimogene filolisbac and ADXS-Dual that are Lm-LLO immunotherapy product candidates for the treatment of human papilloma virus associated cancers, including cervical, and head and neck cancers. The company is also developing Axalimogene filolisbac for the treatment of anal cancer; ADXS-PSA, an Lm-LLO immunotherapy product candidate, which is designed to target the prostate specific antigen associated with prostate cancer; and ADXS-NEO, an individualized Lm technology antigen delivery product candidate that is designed to create individualized therapies by activating the patient's immune system to respond against multiple mutations or neoantigens. In addition, it is developing ADXS-HOT for generating potent anti-cancer immunity; and ADXS-HER2, an Lm technology antigen delivery product candidate that is designed to target HER2 expressing solid tumors, including human and canine osteosarcoma. The company has collaboration and licensing agreements with Bristol-Myers Squibb Company; Amgen Inc.; Sellas Life Science Group; Merck & Co., Inc.; MedImmune/AstraZeneca PLC; Especificos Stendhal SA de CV; Aratana Therapeutics Inc.; and Global BioPharma Inc. Advaxis, Inc. was founded in 2002 and is based in Princeton, New Jersey.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
APPEL RONIDirectorSep 11Buy1.2033,33340,000157,143Sep 13 04:30 PM
PETIT ROBERTChief Scientific OfficerApr 02Sale1.622,1933,553223,500Apr 03 04:30 PM
LOMBARDO ANTHONY AInterim CEOFeb 02Sale2.93329492,903Feb 02 04:30 PM
Bonstein SaraChief Financial OfficerJan 03Sale3.185,22416,612224,013Jan 03 06:00 PM
Bonstein SaraChief Financial OfficerNov 06Sale3.303,86212,745227,908Nov 06 06:00 PM
PETIT ROBERTChief Scientific OfficerNov 06Sale3.303,72312,286220,917Nov 06 06:00 PM
LOMBARDO ANTHONY AInterim CEONov 02Sale3.19247792,935Nov 02 06:00 PM
Bonstein SaraChief Financial OfficerNov 02Sale3.1912,73440,621231,770Nov 02 05:52 PM
PETIT ROBERTChief Scientific OfficerNov 02Sale3.1912,62540,274224,640Nov 02 05:54 PM